Tokyo, Japan and Cambridge, UK, 24 March 2021 – Sosei Group Corporation (“the Company”; TSE: 4565) today confirms its Board and Executive Management appointments in accordance with requirements under the Companies Act. Board appointments were approved at the Company’s 31st Shareholders’ Meeting today and are effective from 24 March 2021. Executive Management appointments were approved at the Company’s Board of Directors meeting today, following earlier announcement at the 31st Shareholders’ Meeting, and are effective from 1 April 2021. Mr. Chris Cargill, currently the Group’s Chief Financial Officer, has been appointed to the additional and new role of Group Chief Operating Officer, reporting to President and Chief Executive Officer, Mr. Shinichi Tamura.
Details of the appointments are as follows:
Board of Directors (effective 24 March 2021)
Chairman of the Board Shinichi Tamura (reappointed)
Independent External Director Tomohiro Tohyama (reappointed)
Independent External Director Kuniaki Kaga (reappointed)
Independent External Director David Roblin (reappointed)
Independent External Director Noriaki Nagai (reappointed)
Independent External Director Rolf Soderstrom (reappointed)
Executive Officers (effective 1 April 2021)
Representative Executive Officer,
Chairman, President and Chief Executive Officer Shinichi Tamura
Executive Vice Chairman Malcolm Weir
Group Chief Operating Officer and Chief Financial Officer Chris Cargill
EVP, Chief Medical Officer Tim Tasker
EVP, Group Chief Compliance Officer Kazuhiko Yoshizumi
EVP, Representative Director President, Sosei Co. Ltd. Tadayoshi Yasui
Chairman, President and CEO, Shinichi Tamura, said: “I would like to congratulate Chris on his expanded role. He has made crucial contributions broadly across the business as we have evolved and executed the Company’s growth strategy over recent years. I am confident that with the current leadership team, Sosei Heptares is well placed to deliver on its goals and generate value for its shareholders.”
Commenting at the 31st Shareholder Meeting, Mr Tamura added: “Sosei Heptares made great progress in 2020 and we are delighted to see this continuing into 2021. This progress has allowed us to successfully execute our strategy focused on leveraging our world-class platform, discovery, and early development capabilities to advance and extend a portfolio of partnered programs. During the past 12 months, we have added several major partnering agreements around our early-stage programs and reinforced our position as a drug discovery and development partner of choice. We also entered several strategic technology collaborations with innovative companies designed to strengthen our platform and enhance our discovery and future partnering opportunities, extending this beyond GPCRs for the first time. In addition, we completed a successful capital raising to support the rapid advancement of our extensive pipeline and our ambitious strategic growth plans, which could include a potentially transformative acquisition. With our clear strategy, our talented team, and a strong financial position, we can look forward to 2021 with great optimism.”
-ENDS-
DOWNLOAD PDF